Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Travoprost 0.004% ophthalmic solution, TRAVATAN Z, Travoprost (TRAVATAN), Travoprost 0.004% ophthalmic solution (TRAVATAN)
TRAVATAN · 1 trial · 2 indications
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
| Arm | Type | Description |
|---|---|---|
| Travatan | EXPERIMENTAL | Travoprost (0.004%) |
| Name | Type | Description |
|---|---|---|
| Travatan | DRUG | Travoprost (0.004%) 1 drop each eye once daily |
Adult patients of any race and either sex with chronic angle-closure glaucoma.
TRAVATAN is used to treat open-angle glaucoma and ocular hypertension. It is an ophthalmology medicine developed by Alcon Inc. and is given once daily. Its clinical development has focused on lowering pressure in the eye in adults aged 18 years and older.
TRAVATAN is made by Alcon Inc., which trades under the ticker ALC. Alcon is the developer associated with the drug's clinical program in ophthalmology, including the long-term safety study conducted in the United States.
TRAVATAN has been studied in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The completed study was a long-term safety study of once-daily TRAVATAN conducted in the United States.
TRAVATAN has been evaluated in the Phase 3 trial NCT00051168, titled A Long-term Safety Study of Once-daily Travatan. That trial enrolled 502 participants with open-angle glaucoma or ocular hypertension, was conducted in the United States, and has been completed.
Across its clinical program, TRAVATAN trials have enrolled a total of 502 participants. That enrollment comes from the completed Phase 3 long-term safety study NCT00051168, which included adults aged 18 years and older of all sexes.
TRAVATAN is dosed once daily. The completed Phase 3 study NCT00051168 was designed as a long-term safety study of once-daily TRAVATAN in patients with open-angle glaucoma or ocular hypertension, and it enrolled 502 participants in the United States.